Sage Therapeutics Management

Management criteria checks 2/4

Sage Therapeutics' CEO is Barry Greene, appointed in Dec 2020, has a tenure of 3.42 years. total yearly compensation is $6.24M, comprised of 12.8% salary and 87.2% bonuses, including company stock and options. directly owns 0.078% of the company’s shares, worth $654.37K. The average tenure of the management team and the board of directors is 3.5 years and 9.7 years respectively.

Key information

Barry Greene

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage	12.8%
CEO tenure	3.4yrs
CEO ownership	0.08%
Management average tenure	3.5yrs
Board average tenure	9.7yrs

Recent management updates

Recent updates

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Feb 22

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Feb 15

Sizing Up Sage Therapeutics

Jan 22

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Aug 09

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Feb 22

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Nov 12

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Oct 14

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Aug 02

What You Need To Know About The Sage Therapeutics, Inc. (NASDAQ:SAGE) Analyst Downgrade Today

Aug 05

Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns

Jul 25

Sage Therapeutics Needs To Show Improved Data To Regain Investor Trust

Jul 12

Sage Therapeutics Q1 2021 Earnings Preview

May 03

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

Feb 26

CEO Compensation Analysis

How has Barry Greene's remuneration changed compared to Sage Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$503m
Dec 31 2023	US$6m	US$799k	-US$541m
Sep 30 2023	n/a	n/a	-US$656m
Jun 30 2023	n/a	n/a	-US$592m
Mar 31 2023	n/a	n/a	-US$558m
Dec 31 2022	US$6m	US$761k	-US$533m
Sep 30 2022	n/a	n/a	-US$510m
Jun 30 2022	n/a	n/a	-US$503m
Mar 31 2022	n/a	n/a	-US$484m
Dec 31 2021	US$59m	US$735k	-US$458m
Sep 30 2021	n/a	n/a	US$642m
Jun 30 2021	n/a	n/a	US$666m
Mar 31 2021	n/a	n/a	US$637m
Dec 31 2020	US$836k	US$53k	US$606m

Compensation vs Market: Barry's total compensation ($USD6.24M) is above average for companies of similar size in the US market ($USD3.42M).

Compensation vs Earnings: Barry's compensation has increased whilst the company is unprofitable.

CEO

Barry Greene (60 yo)

3.4yrs

Tenure

US$6,237,491

Compensation

Mr. Barry E. Greene serves as President and Chief Executive Officer at Sage Therapeutics, Inc. since December 15, 2020 and its Director since October 1, 2020. Mr. Greene joined the Sage Therapeutics, Inc....

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Barry Greene	President	3.4yrs	US$6.24m	0.078% $ 654.4k
Kimi Iguchi	CFO & Treasurer	11.2yrs	US$1.98m	0.12% $ 981.8k
Anne Cook	Senior VP	8.7yrs	US$2.15m	0.023% $ 194.2k
Christopher Benecchi	Chief Business Officer	2.7yrs	US$2.28m	0.0098% $ 82.6k
Laura Gault	Chief Medical Officer	1.6yrs	US$1.27m	0.00038% $ 3.2k
Matt Lasmanis	Chief Technology & Innovation Officer	3.5yrs	no data	no data
Mike Quirk	Chief Scientific Officer	less than a year	no data	no data
Ashley Kaplowitz	Director of Investor Relations	no data	no data	no data
Erin Lanciani	Chief People & Experience Officer	no data	no data	no data
Amy Schacterle	Senior Vice President of R&D Strategy and Business Management	7.1yrs	no data	no data
Heinrich Schlieker	Senior Vice President of Technical Operations	3.5yrs	no data	no data
Helen Colquhoun	Senior Vice President of Drug Safety & Pharmacovigilance	no data	no data	no data

3.5yrs

Average Tenure

57yo

Average Age

Experienced Management: SAGE's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Barry Greene	President	3.6yrs	US$6.24m	0.078% $ 654.4k
Michael Cola	Independent Director	9.7yrs	US$440.05k	0% $ 0
James Frates	Independent Director	10yrs	US$435.05k	0.0047% $ 39.7k
Steven Paul	Independent Director	12.7yrs	US$420.05k	0.86% $ 7.2m
David Farb	Member of Scientific Advisory Board	no data	no data	no data
Geno Germano	Independent Chair of the Board	7.8yrs	US$417.55k	0% $ 0
Michael Rogawski	Member of Scientific Advisory Board	no data	no data	no data
James Audia	Member of Scientific Advisory Board	no data	no data	no data
Christine Marx	Member of Scientific Advisory Board	no data	no data	no data
A. Morrow	Member of Scientific Advisory Board	no data	no data	no data
Stephen Moss	Member of Scientific Advisory Board	no data	no data	no data
Scott Runyon	Member of Scientific Advisory Board	no data	no data	no data

9.7yrs

Average Tenure

62.5yo

Average Age

Experienced Board: SAGE's board of directors are considered experienced (9.7 years average tenure).

Sage Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Insufficient new directors

Insider recently bought US$51k worth of stock

President recently bought US$500k worth of stock

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Recent updates

Consensus revenue estimates increase by 32%, EPS downgraded

Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 13% to US$24.39

Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease

Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Analysts Have Just Cut Their Sage Therapeutics, Inc. (NASDAQ:SAGE) Revenue Estimates By 50%

Consensus revenue estimates fall by 50%

Consensus revenue estimates fall by 50%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Calculating The Fair Value Of Sage Therapeutics, Inc. (NASDAQ:SAGE)

Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024

Sizing Up Sage Therapeutics

Price target decreased by 13% to US$21.94

Sage Therapeutics, Inc. Announces Changes to Board of Directors

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Insufficient new directors

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million.

Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease

Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%

Consensus revenue estimates fall by 57%

Things Look Grim For Sage Therapeutics, Inc. (NASDAQ:SAGE) After Today's Downgrade

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 21% to US$48.06

Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Insider recently bought US$51k worth of stock

Consensus revenue estimates increase by 14%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

President recently bought US$500k worth of stock

An Intrinsic Calculation For Sage Therapeutics, Inc. (NASDAQ:SAGE) Suggests It's 45% Undervalued

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer

Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer

Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress

Here's Why We're Not Too Worried About Sage Therapeutics' (NASDAQ:SAGE) Cash Burn Situation

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Sage Therapeutics GAAP EPS of -$2.13 beats by $0.02, revenue of $1.5M misses by $0.27M

Sage Therapeutics, Inc. Enters into Settlement Agreement

Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update

Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints

Consensus revenue estimates fall by 62%

Insider recently bought US$252k worth of stock

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD)

Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease

Sage Therapeutics: Well-Funded But Uninspiring Data

Consensus revenue estimates fall by 58%

We're Hopeful That Sage Therapeutics (NASDAQ:SAGE) Will Use Its Cash Wisely

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Sage Therapeutics, Inc. Provides Business Update

Price target decreased to US$67.60

Sage Therapeutics, Inc and Biogen Inc Announce Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints

Investor sentiment deteriorated over the past week

Sage Therapeutics: Biogen's Backing May See It Through

Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology Congress

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

Third quarter 2021 earnings released: US$2.21 loss per share (vs US$2.03 loss in 3Q 2020)